|1.||Marson, Anthony G: 3 articles (01/2015 - 01/2013)|
|2.||Sills, Graeme J: 3 articles (01/2015 - 01/2013)|
|3.||Powell, Graham: 3 articles (01/2015 - 01/2013)|
|4.||Milburn-McNulty, Philip: 3 articles (01/2015 - 01/2013)|
|5.||Bast, Thomas: 2 articles (09/2013 - 02/2003)|
|6.||Stephani, Ulrich: 2 articles (11/2006 - 01/2006)|
|7.||Ben-Zeev, Bruria: 2 articles (10/2004 - 12/2002)|
|8.||Watemberg, Nathan: 2 articles (10/2004 - 12/2002)|
|9.||Lerman-Sagie, Tally: 2 articles (10/2004 - 12/2002)|
|10.||Debus, Otfried Martin: 2 articles (02/2004 - 09/2002)|
01/01/2009 - "Therefore, we conclude that sulthiame is an effective and safe antiepileptic drug for the treatment of intractable epilepsy."
01/01/2008 - "The purpose of this study was to determine if reduction in spike frequency in children with benign epilepsy of childhood with centrotemporal spikes treated with sulthiame correlates with improved neuropsychologic function. "
01/01/2015 - "Large, multi-centre randomized controlled trials are necessary to inform clinical practice if sulthiame is to be used as an add-on therapy for epilepsy."
01/01/2015 - "Randomised controlled add-on trials of sulthiame in people of any age with epilepsy of any aetiology. "
01/01/2013 - "Large, multi-centre randomised controlled trials are necessary to inform clinical practice if sulthiame is to be used as an add-on therapy for epilepsy."
01/01/2014 - "One study, a placebo-controlled trial with a low risk of bias, found that individuals on sulthiame were significantly more likely to remain in seizure remission during the three and six months from commencement of treatment than those on placebo (3 months: RR 2.26, 95% CI 1.48 to 3.44; 6 months: RR 2.63, 95% CI 1.43 to 4.86, 66 participants, moderate quality evidence). "
07/01/2012 - "Since add-on of sulthiame, 10 of 28 patients in the symptomatic group became seizure free: 4 patients with normal EEG studies and 6 with residual spikes. "
01/01/2008 - "All children continued receiving sulthiame monotherapy (dose range, 8.0-9.3 mg/kg per day) for the study period without further seizures. "
04/01/2003 - "The effect of Sulthiame on the EEG and on clinical seizures was evaluated in an open uncontrolled study in 25 children with focal sharp waves on the EEG (FSW). "
07/01/2012 - "Twenty-one of the 25 patients in the idiopathic group became seizure free and without ESES in <3 months after add on of sulthiame. "
|3.||Rolandic Epilepsy (Centrotemporal Epilepsy)
01/01/2005 - "Thirty-nine children with BECTS from our department (aged 3-11 years) were analyzed as candidates to be enrolled in a prospective multicenter randomized double-blind placebo controlled study on therapeutic efficacy of sulthiame. "
02/01/1999 - "A previously unpublished side effect of sulthiame in a patient with Rolandic epilepsy."
01/01/2014 - "There is evidence from one trial reviewed that sulthiame is effective for seizure remission in the short term in children with BECTS although the precision of the effect estimate is uncertain due to its small sample size. "
02/01/2003 - "The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS)."
10/01/2000 - "To evaluate the efficacy and tolerability of sulthiame (STM) as monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS). "
|4.||Learning Disorders (Learning Disability)
01/01/2006 - "Recently, 21 patients without epilepsy but with attention deficit and hyperactivity and/or learning disorders were studied: an open treatment trial with sulthiame resulted in improved sustained and selective attention. "
08/01/2002 - "This prospective uncontrolled open study explored the efficacy and long-term tolerability of sulthiame (STM) in 52 patients with refractory epilepsy and learning disability. "
08/01/2002 - "Sulthiame in adults with refractory epilepsy and learning disability: an open trial."
|5.||Partial Epilepsies (Epilepsy, Partial)
02/01/2004 - "Sulthiame (STM), which is commonly used in some countries in the treatment of benign focal epilepsies in childhood, has been suggested to be effective in WS too. "
12/01/1996 - "Sulthiame is effectively used in the treatment of benign and symptomatic focal epilepsy in children. "
10/01/1988 - "Benign partial epilepsy--treatment with sulthiame."
07/01/2012 - "Sulthiame add-on therapy in children with focal epilepsies associated with encephalopathy related to electrical status epilepticus during slow sleep (ESES)."
10/01/2004 - "The high tolerability, efficacy, convenience of use and low cost suggest that sulthiame should become a first line drug in the benign partial epilepsies of childhood and juvenile myoclonic epilepsy. "
|3.||Carbonic Anhydrases (Carbonic Anhydrase)
|9.||clobazam (HR 376)
|1.||Drug Therapy (Chemotherapy)